WO2019193381A1 - Composition pour le traitement de l'hépatite b - Google Patents

Composition pour le traitement de l'hépatite b Download PDF

Info

Publication number
WO2019193381A1
WO2019193381A1 PCT/IB2018/001473 IB2018001473W WO2019193381A1 WO 2019193381 A1 WO2019193381 A1 WO 2019193381A1 IB 2018001473 W IB2018001473 W IB 2018001473W WO 2019193381 A1 WO2019193381 A1 WO 2019193381A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus
composition
ascorbic acid
cyanocobalamin
Prior art date
Application number
PCT/IB2018/001473
Other languages
English (en)
Inventor
Thi Trieu NGUYEN
Minh Duc Tran
Original Assignee
Thi Trieu NGUYEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thi Trieu NGUYEN filed Critical Thi Trieu NGUYEN
Publication of WO2019193381A1 publication Critical patent/WO2019193381A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the invention relates to the pharmaceutical composition, in particular, the invention to kill of human hepatitis B virus.
  • the invention consists of the following components: the concentrated essence of Adenosma Glutinosum; the concentrated essence of Eclipta Prostrata; the concentrated essence of Phyllanthus Urinaria; Ascorbic acid; Cyanocobalamin.
  • the composition will contain the following components: the concentrated essence of Adenosma Glutinosum; the concentrated essence of Eclipta Prostrata; the concentrated essence of
  • the present invention provides a composition for the treatment of a hepatitis B virus in which the composition comprises the following components (in % by weight):
  • Concentrated essence of Adenosma Glutinosum, Eclipta Prostrata, Phyllanthus Urinaria are obtained by harvesting Adenosma Glutinosum, Eclipta Prostrata, Phyllanthus Urinaria during the flowering season and drying, high-boiling, makes maximum evaporation, makes concentrated substance create density to obtain the desired chemical composition.
  • Adenosma Glutinosum has Saponin Triterpenoid; Saponin Steroid; Flavonoid; 6,7 - Dimethoxy; Coumarin; Cineol. It has anti-inflammatory, analgesic and anti-allergy properties, improve immunity and inhibit the development of cancer cells.
  • Eclipta Prostrata has containing alkaloids ecliptic, nicotine and coumarin. Eclipta Prostrata tasks the protect blood vessels, anti-inflammation, analgesic, anti-allergy.
  • Phyllanthus Urinaria has flavonoids; Phyllanthus alkaloid; Phyllanthus Urinaria has analgesic, anti-inflammatory, diuretic, has inhibitory properties DNA polymerase of the virus.
  • Flavonoids can act as a chemical transfer agent or physiological regulator. Flavonoids can also act as cell cycle inhibitors.
  • Alkaloid Phyllanthine restores the antioxidant capacity of the liver cells, protecting the liver cells.
  • Coumarin's derivatives have anti-fungal, anti-tumor, anti-coagulant, anti-viral effects.
  • Triterpenoid is synthesized by plants, is an anti-cancer agent that protects cells.
  • Steroids utilize two biological functions that are important components of cell membranes that alter cell membrane mobility and signal transfer at the cellular level.
  • Steroids have a variety of biological, pharmacological, and positive effects on human health. Sterols are special types of specific steroids found in plants with antioxidant properties, with evidence that sterols have an effect on inflammatory responses to hepatitis B virus, hepatitis C, HIV, stress reduction, etc.
  • Ascorbic acid is an essential nutrient for humans. Ascorbic acid is readily distributed in high concentrations in immune cells, has natural antibacterial activity, promote increased bioavailability. Promotes the growth and reproduction of Lymphocytes, and are consumed rapidly during the infection, the effects showing a prominent role in regulating the immune system.
  • Cyanocobalamin is essential for the production of blood, carbohydrates, fats and proteins, and the production of DNA and RNA.
  • the components present will create the direction to destroy the virus in a new step, innovative way.
  • the active ingredient When some of the metabolites require the presence of these active ingredients, the active ingredient will play the role of producing the immune system against the virus, anti-inflammatory, and help the body fight the hepatitis B virus disease.
  • the metabolites obtained during the digestion process undergoes alteration in the intestinal tract, by microorganisms and enterocyte enzymes being absorbed in the cellular and colon levels, this enhances beneficial effects treatment for the patient, including a series of protective effects against the entry of the virus, creating an unfavorable environment for the reproductive virus and developing, creating a viral rejection environment.
  • the special environment when the presence of active ingredients substances in this composition increases the effectiveness of nucleoside reverse transcriptase inhibitors.
  • the invention provides a composition for the treatment of hepatitis B virus, wherein the composition comprises the following components
  • This preparation is given in the form of 1500mg tablets at a dose of 1 capsule once daily.
  • Hepatitis B surface antigen (+) for a minimum of 6 months prior to treatment.
  • Hepatitis B envelope antigen (+) or (-) at baseline.
  • Hepatitis B surface antigen (HBsAg)(+) for at least 6 months prior to application.
  • Test subjects are divided into two groups Group 1 : Control group, placebo.
  • the trial period was 12 months.
  • test data is based on
  • Results showed that the placebo group did not show any positive signs.
  • 100% of the respondents were satisfied. It has been shown that the composition of the present invention has the effect of enhancing the ability to kill the virus, regenerating the liver cells.
  • the first use of the combination of pharmaceutical will result in a chain reaction that is good in treating the disease.
  • By studying the combination of chemical components in this composition it will to action as interferon to remove the virus in the patient's body.
  • the catalyst works well to prevent the multiplication of the virus, they can act as real enzymes or analogy protein enzymes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention est utilisée pour tuer le virus de l'hépatite B, comprenant l'essence concentrée d'Adenosma Glutinosum; l'essence concentrée d'Eclipta Prostrata; l'essence concentrée de Phyllanthus Urinaria; l'acide ascorbique; la cyanocobalamine.
PCT/IB2018/001473 2018-04-05 2018-12-24 Composition pour le traitement de l'hépatite b WO2019193381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN1-2018-01445 2018-04-05
VN201801445 2018-04-05

Publications (1)

Publication Number Publication Date
WO2019193381A1 true WO2019193381A1 (fr) 2019-10-10

Family

ID=65268993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/001473 WO2019193381A1 (fr) 2018-04-05 2018-12-24 Composition pour le traitement de l'hépatite b

Country Status (1)

Country Link
WO (1) WO2019193381A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069195A (zh) * 1991-08-07 1993-02-24 安康地区药品检验所 一种肝炎药物的制取方法
WO1998007437A1 (fr) * 1996-08-16 1998-02-26 Hepaguard Co., Ltd. COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'HEPATITE B A BASE D'EXTRAIT DE Phyllanthus ussuriensis ET/OU DE $i(Phyllanthus urinaria)
WO2003030929A1 (fr) * 2001-10-05 2003-04-17 Transition Therapeutics Inc. Polytherapies faisant intervenir des donneurs de methyle et des activateurs de donneurs de methyle ainsi que des agents therapeutiques pour le traitement de maladies virales, proliferatives et inflammatoires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069195A (zh) * 1991-08-07 1993-02-24 安康地区药品检验所 一种肝炎药物的制取方法
WO1998007437A1 (fr) * 1996-08-16 1998-02-26 Hepaguard Co., Ltd. COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'HEPATITE B A BASE D'EXTRAIT DE Phyllanthus ussuriensis ET/OU DE $i(Phyllanthus urinaria)
WO2003030929A1 (fr) * 2001-10-05 2003-04-17 Transition Therapeutics Inc. Polytherapies faisant intervenir des donneurs de methyle et des activateurs de donneurs de methyle ainsi que des agents therapeutiques pour le traitement de maladies virales, proliferatives et inflammatoires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Tenofovir Disoproxil Fumarat , Herbal Medicaments, Vitamin C Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B (HBV)", 8 October 2015 (2015-10-08), XP002790581, Retrieved from the Internet <URL:https://web.archive.org/web/20151008083843/https://clinicaltrials.gov/ct2/show/NCT01198860> [retrieved on 20190412] *
DATABASE WPI Week 199401, Derwent World Patents Index; AN 1994-000163, XP002790583 *
DR NARENDRAKUMAR P. PALIWAL, DR BHARGAV M PUROHIT, DR C B TRIPATHI, DR HEMANGINI R ACHARYA, DR MAHENDRA K PATEL: "Evaluation of anti-inflammatory, analgesic and antipyretic activity of Eclipta alba (Linn.) Hassk. in experimental animals", EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH, vol. 4, no. 3, 24 January 2017 (2017-01-24), pages 391 - 399, XP002790582 *
GRACE RATTUE: "Hepatitis C May Be Treated With Vitamin B12", 27 April 2017 (2017-04-27), XP002790584, Retrieved from the Internet <URL:https://web.archive.org/web/20170427092052/https://www.medicalnewstoday.com/articles/247986.php> [retrieved on 20190412] *
NGUYEN THI TREU & TRAN MINH DUC: "Herbal medicaments, ascorbic acid, Tenofovir, treatment on HBeAg positive or HbeAg negative in chronic hepatitis B (A combination of treatment with herbals)", PEDIATRIC INFECTIOUS DISEASES, vol. 2, no. 1:32, 26 December 2016 (2016-12-26), pages 1 - 2, XP002790580, Retrieved from the Internet <URL:https://pediatric-infectious-disease.imedpub.com/herbal-medicaments-ascorbic-acid-tenofovir-treatment-on-hbeag-positive-or-hbeag-negative-in-chronic-hepatitis-b-a-combination-of-t.pdf> [retrieved on 20190412], DOI: 10.21767/2573-0282.100032 *
WU YING ET AL: "Extract from Phyllanthus urinaria L. inhibits hepatitis B virus replication and expression in hepatitis B virus transfection model in vitro", CHINESE JOURNAL OF INTEGRATED MEDICINE /ZHONGGUO JIEHE YIXUE ZAZHI (ENGLISH), ZHONGGUO ZHONG-XIYI JIEHE YANJIUHUI, CN, vol. 21, no. 12, 13 April 2015 (2015-04-13), pages 938 - 943, XP035944013, ISSN: 1672-0415, [retrieved on 20150413], DOI: 10.1007/S11655-015-2076-7 *

Similar Documents

Publication Publication Date Title
Diwanay et al. Immunoprotection by botanical drugs in cancer chemotherapy
Matsuse et al. A search for anti-viral properties in Panamanian medicinal plants.: The effects on HIV and its essential enzymes
EP1096943B1 (fr) Procede de preparation et composition pharmaceutique d&#39;un extrait de l&#39;espece vegetale uncaria soluble dans l&#39;eau
US6589570B1 (en) Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
Osagie-Eweka et al. Oral acute and sub-chronic toxicity assessment of aqueous leaf extract of Simarouba glauca DC (Paradise tree)
CN100497279C (zh) 一类对映桉烷醇类倍半萜抑制乙肝病毒的医药用途
EP0199429A2 (fr) Préparation d&#39;un médicament pour traiter l&#39;hépatite virale
Nikolaou et al. Accidental poisoning after ingestion of “aphrodisiac” berries: diagnosis by analytical toxicology
CN104208070B (zh) 蒲公英甾醇在制备抗hbv的药物中的应用
KR19990015612A (ko) 황백피와 마타리 식물의 혼합추출물을 함유하는 c형 간염 치료제조성물
KR100414187B1 (ko) 흰점박이꽃무지 추출물 및 이의 용도
WO2019193381A1 (fr) Composition pour le traitement de l&#39;hépatite b
CN101695511B (zh) 石榴皮提取物及其生产方法和应用
US9084758B2 (en) Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof
Sharma et al. Hepatoprotective activity of Cnidoscolus Phyllacanthus leaves against D-galactosamine induced hepatotoxicity in Rats
CN110279752B (zh) 速生桉叶提取物及其制备方法和抗hiv应用
KR100370501B1 (ko) 금은화추출물을포함하는비형간염치료제
Bothiraja et al. In vitro anti-HIV-type 1 and antioxidant activity of Emblica officinalis
Ibama et al. Comparative Effects of Sildenafil Citrate and Revive Capsule on Some Liver and Kidney Parameters in Male Albino Rats
CN1935131B (zh) 1β-羟基冬青酸用于制备抑制乙肝病毒的药物用途
RU2698325C1 (ru) Сок из свежих плодов боярышника мягковатого, обладающий диуретической активностью
Rakhimova et al. HERBAL MEDICINE IN THE TREATMENT OF LIVER DISEASES
CN100494157C (zh) 一种桉烷型倍半萜酸及其应用
Iroanya et al. Effect of a polyherbal mixture on acetaminophen induced hepato-nephro toxicity in rats
Wahyuni et al. Anti-Hepatitis C Activity of Combination of Ruta angustifolia Extract and Ribavirin.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18842644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.02.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 18842644

Country of ref document: EP

Kind code of ref document: A1